pre-IPO PHARMA

COMPANY OVERVIEW

Avillion's objective is to enable their partners to continue to develop their most important drug candidates without increasing the burden on their P&L or cash reserves


LOCATION

  • London, , UK

  • THERAPEUTIC AREAS


    WEBSITE

    https://avillionllp.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    abingworth clarus-ventures royalty-pharma


    PRESS RELEASES


    May 31, 2022

    US FDA accepts New Drug Application filed by Avillion for AstraZeneca's PT027 for the as-needed treatment or prevention of symptoms in asthma patients


    May 15, 2022

    Avillion announces publication of positive full results from MANDALA Phase III trial of AstraZeneca's PT027 in asthma patients in the New England Journal of Medicine


    Sep 9, 2021

    Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca's PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients


    Apr 23, 2021

    Avillion's positive Phase 2 trial of tri-specific Nanobody sonelokimab (M1095) in chronic psoriasis published in The Lancet


    Oct 29, 2020

    Positive results from Avillion's Phase 2 trial of sonelokinab (M1095) in chronic psoriasis to be presented today in Late-Breaking News Session at EADV 2020 Virtual


    For More Press Releases


    Google Analytics Alternative